KPE 00001128

Drug Profile

KPE 00001128

Alternative Names: KPE00001128

Latest Information Update: 13 Mar 2008

Price : $50

At a glance

  • Originator Kemin Pharma
  • Class Antivirals; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 13 Mar 2008 Discontinued - Preclinical for Herpes simplex virus infections in Belgium (unspecified route)
  • 25 Mar 2004 Preclinical trials in Herpes simplex virus infections treatment in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top